Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
– Results Demonstrate AAV9 Gene Therapy of LAMP2B Reverses Clinical Manifestations of Danon Disease in Mouse Study – NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the peer-reviewed publication of a study evaluating the efficacy of an adeno-associated virus (AAV)-based gene therapy delivering human LAMP2B in a mouse model of Danon Disease, a rare genetic disorder often resulting in heart failure. The Science Translational Medicine publication “AAV9.LAMP2B Reverses Metabolic and Physiologic Multiorgan Dysfunction in a Murine Model of Danon Disease” describes data demonstrating that vector-mediated transfer of LAMP2B to deficient mice improved heart function and survival. These findings underscore the promise of Rocket’s AAV-based gene therapy candidate for Danon Disease, RP-A501.In this study, researchers eva
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Leerink Partners from $46.00 to $44.00. They now have an "outperform" rating on the stock.MarketBeat
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.MarketBeat
RCKT
Earnings
- 11/7/24 - Beat
RCKT
Sec Filings
- 11/21/24 - Form 144
- 11/21/24 - Form 144
- 11/21/24 - Form 144
- RCKT's page on the SEC website